Nobuo Hatakeyama

Kochi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Tumor Necrosis on Routine Pretreatment CT as a Potential Prognostic Marker in Advanced NSCLC Treated With Immune Checkpoint Inhibitor Monotherapy: A Two-Center Retrospective Study.

Tumor Necrosis on Routine Pretreatment CT as a Potential Prognostic Marker in Advanced NSCLC Treated With Immune Checkpoint Inhibitor Monotherapy: A Two-Center Retrospective Study.

Journal: Thoracic cancer

Published: March 06, 2026

Successful pembrolizumab treatment in a patient with ALK-positive lung adenocarcinoma: A case report and literature review.

Successful pembrolizumab treatment in a patient with ALK-positive lung adenocarcinoma: A case report and literature review.

Journal: Medicine

Published: July 15, 2025

Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non-small cell lung cancer.

Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non-small cell lung cancer.

Journal: International journal of cancer

Published: February 21, 2025

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.

Journal: Cancer reports (Hoboken, N.J.)

Published: January 27, 2025

Pathological Complete Response to a Single Dose of Pembrolizumab-Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report.

Pathological Complete Response to a Single Dose of Pembrolizumab-Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report.

Journal: Thoracic cancer

Published: October 09, 2024

An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Journal: Thoracic cancer

Published: September 13, 2023

Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Journal: Thoracic cancer

Published: July 21, 2023

Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.

Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.

Journal: Thoracic cancer

Published: November 07, 2022

Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.

Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.

Journal: Thoracic cancer

Published: October 18, 2022

An 18 F-FDG-PET-Positive Mucoid Impaction With Ring Enhancement on CT Mimicking Lung Cancer.

An 18 F-FDG-PET-Positive Mucoid Impaction With Ring Enhancement on CT Mimicking Lung Cancer.

Journal: Clinical nuclear medicine

Published: April 29, 2022

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.

Journal: Journal of cancer research and clinical oncology

Published: April 06, 2022

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.

Journal: Thoracic cancer

Published: October 24, 2021

Showing 1-12 of 32

Last Updated: 09/26/2026